Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Mepolizumab 100mg SC; Drug: Albuterol/salbutamol MDIs; Drug: Omalizumab
Sponsor: GlaxoSmithKline
Not yet recruiting – verified January 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Omalizumab Highly Effective in Reducing Severe Asthma Symptoms
Monthly Prescribing Reference (registration) Ivo Abraham, PhD, RN, from the University of Arizona in Tucson, and colleagues reviewed 24 real-life effectiveness studies of omalizumab in the treatment of severe allergic asthma. The studies included 4,117 unique patients from 32 countries … |
View full post on asthma – Google News
|
Omalizumab Highly Effective for Severe Allergic Asthma
Monthly Prescribing Reference (registration) Ivo Abraham, PhD, RN, from the University of Arizona in Tucson, and colleagues reviewed 24 real-life effectiveness studies of omalizumab in the treatment of severe allergic asthma. The studies included 4,117 unique patients from 32 countries … |
View full post on asthma – Google News
|
Omalizumab reduces exacerbation rate in children with asthma
Healio Teach and colleagues conducted a double blind, double placebo-controlled study of 478 children with asthma aged 6 to 17 years old who lived in the inner city. Study participants — all of whom had a recent asthma exacerbation — were randomly assigned … |
View full post on asthma – Google News
MD Magazine |
Adherence to Omalizumab Does Not Correlate with Better Response for Asthma
MD Magazine While clinicians should always encourage their patients to follow their medication schedules, it proved not to be a significant factor in the outcomes in patients with asthma taking omalizumab, according to a poster session at the 2015 American College … |
View full post on asthma – Google News
|
Study Tests Effectiveness of Omalizumab in Treating Perennial Severe Allergic …
Lung Disease News Asthma is a common chronic condition of the airways that is complex and characterized by variable and regular symptoms, airflow obstruction, bronchial hyper responsiveness and inflammation. Asthma may be classified clinically on the basis of various … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: omalizumab; Biological: Rhinovirus (strain 16)
Sponsors: University of Virginia; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting – verified March 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Omalizumab use in pregnancy showed comparable birth results with asthma …
Healio Prevalence of congenital defects, prematurity and low birth weight in infants of mothers treated with omalizumab during pregnancy were comparable with the general population with asthma, according to recent study results. “Asthma affected 8.4% to 8.8 … |
View full post on asthma – Google News
Condition: Colon Cancer
Intervention: Drug: Omalizumab
Sponsor: Yale University
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Omalizumab effectively treated adults with severe refractory asthma
Healio Omalizumab was effective in treating adults with severe refractory asthma for up to 48 weeks, possibly exerting anti-inflammatory effects on small airways and reversing airway remodeling, according to recent study results. Researchers in Japan … |
View full post on asthma – Google News